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Abstract
Objective:  To evaluate the functionality of the auditory system in patients who underwent
radiotherapy and chemotherapy treatment with cisplatin to treat head and neck tumors.
Study Design: Case series with planned data collection.
Setting:  From May 2007 to May 2008 by the Department of Otorhinolaryngology and the
Department of Oncology/Radiotherapy at Faculdade de Medicina de Marília.
Subjects and Methods: Audiological evaluation (Pure Tone Audiometry (air and bone
conduction), Speech Audiometry, Tympanometry, Acoustic Reflex testing and Distortion Product
Otoacoustic Emissions) was performed in 17 patients diagnosed with head and neck neoplasia and
treated with chemotherapy, using cisplatin, and radiotherapy.
Results: 12 left ears (70.5%) and 11 right ears (64.7%) presented bilateral decreased hearing soon
after the treatment for the frequency 1 kHz (mild auditory damage) and for the frequency 8 kHz
(more significant auditory damage).
Conclusion: Patients with head and neck cancer submitted to the conventional radiotherapy
treatment, combined with the chemotherapy with cisplatin, presented a high incidence of
decreased hearing by the end of treatment. Strong evidence was observed linking auditory
alteration to the amount of radiotherapy treatment.
Introduction
Auditory damage is one of the main complications of
oncological therapy in patients with head and neck
tumors [1]. Recently, the addition of chemotherapy (CT)
with cisplatin to radiotherapy (RT) has been improving
the survival rate of patients with these neoplasias, becom-
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ing a standard treatment for tumors locally advanced.
However, both treatments, chemotherapy with cisplatin
and radiotherapy, are known for their ototoxic effects.
As the combined treatment became the standard proce-
dure in many cases of head and neck tumors, the objective
of this study is to evaluate the changes in auditory func-
tion in patients submitted to these procedures regarding
their ototoxic effects; to describe the incidence of the pre-
cocious auditory damages after the combined treatment;
to establish a link between the findings obtained and the
factors related to the treatment, including the cumulative
dose of chemotherapy, the total dose of radiotherapy, and
the volume irradiated by the radiotherapy (VTRT).
Methods and materials
Case series with planned data collection performed by the
Department of Otorhinolaryngology and the Department
of Oncology/Radiotherapy at Faculdade de Medicina de
Marília  (FAMEMA), approved by the Research Ethics
Committee under protocol # 165/06.
The study involved 17 patients (15 males and 2 females,
in a total of 34 ears) that were scheduled for chemoradia-
tion treatment for extracranial head and neck tumors,
from May 2007 to May 2008. All patients agreed to
undergo hearing tests and all provided written informed
consent for participation in this study.
After having the diagnosis of neoplasia confirmed by the
anatomopathological examination, and being indicated
this combined treatment, the patients were directed to the
Otorhinolaryngology clinic at FAMEMA's General Hospi-
tal (Hospital das Clínicas) for otorhinolaryngological and
audiological evaluation, which consisted of two stages:
pre- and post-treatment (within 2 weeks after treatment).
In these stages, the following procedures were used:
Anamnesis and Clínical Otorhinolaryngological Evalua-
tion, Audiological Anamnesis, Pure Tone Audiometry by
air and bone conduction, Speech Audiometry, Tympan-
ometry, Acoustic Reflex testing and Distortion Product
Otoacoustic Emissions (DPOAE).
Patients with otitis media with effusion, hearing loss due
to a significant noise exposure, trauma, ototoxic medica-
tion, neoplasm, and congenital infection or syndrome,
congenital or pediatric onset, with nasopharyngeal
tumors and those who previously received chemo and/or
radiotherapy were excluded from the study.
In the Department of Oncology/Radiotherapy, all patients
underwent a complete physical examination, direct or
indirect laryngoscopy, head and neck computerized tom-
ography and thorax X-ray before the treatment.
Weekly doses of intravenous cisplatin (30 mg/m2) as first
infusion of the drug in the first day of the radiotherapy
was prescribed to the patients.
This prescribed radiotherapy dose varied according to the
primary site of the disease and the primary tumor staging.
Before beginning the radiotherapy sessions, the patients
were submitted to the conventional simulation (X-ray) for
delimitation of the radiotherapy site and to make molded
thermoplastic masks, used to immobilize the patient in
supine position and to mark the area to be treated.
The treatment limits (radiation area) varied according to
the primary site of the pathology. However, due to the
advanced nature of the cases, all the patients had the supe-
rior border of the radiotherapy site in the base of the cra-
nium, thus including the cochlea in the radiotherapy area.
To calculate the volume of radiotherapy treatment (VRT)
we used the patient's latero-lateral distance, measured
during the simulation process, multiplied by the resulting
area of the simulation area for each patient.
Statistical analysis
To analyze the differences in the tonal threshold averages
for each frequency, pre and post treatment, we performed
the T - Student Test.
To determine which values (variables: age, volume and
dose of RT and total dose of CT) would have some rela-
tion to the reduction of the tonal thresholds in the post-
treatment, the Fisher Exact Test was applied. According to
the Contingency table, the Odds Ratio was calculated to
determine the relation between the probability of occur-
rence to the probability of non-occurrence of an auditory
alteration after chemo- and concomitant radiotherapy
treatment, taking into consideration the variables: age,
volume and dose of RT, and total dose of CT.
We considered as reduction of the auditory acuity, the
decrease of 20 dB in an isolated frequency or of 10 dB in
two or more successive frequencies, according to the
ASHA criteria [2].
For all the statistical tests, a value up to 5% for the signif-
icance level (value of p < 0.05) was considered.
Results
The patient's characteristics including age, gender, tumor
histology, distribution by clinical staging, number of
chemotherapy cycles, cumulative dose of cisplatin, frac-
tioned and total dose of radiotherapy, and the volume of
radiotherapy treatment are described on Table 1.Radiation Oncology 2009, 4:53 http://www.ro-journal.com/content/4/1/53
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All the patients received at least 2 chemotherapy cycles,
and three patients received 8 cycles resulting in an average
dose of 299 mg/m2 and median of 315 mg/m2 with varia-
tion from 96 to 455 mg/m2.
The total dose of the radiotherapy varied from 60.0 Gy to
72.0 Gy, being the average dose of 68.9 Gy and median of
the dose of 72.2 Gy, with a variation of the daily dose
from 1.8 Gy to 2.0 Gy.
Regarding the VRT, we have found an average volume of
1,853 cm3 and median of 1,500 cm3 with variation of 739
cm3 - 3,364 cm3.
Out of 17 patients and 34 ears analyzed, we observed dur-
ing the otorhinolaryngological evaluation that 2 ears pre-
sented perforated tympanic membrane and 32 normal
membranes. Alterations during the chemo and radiother-
apy treatment were not observed in the otoscopy.
Regarding the audiological evaluations performed before
the radio and chemotherapy treatments, it was observed
in our sample that only 2 ears presented thresholds within
the normal patterns (lower than 20 dB) and most of the
patients analyzed had already presented some type of
auditory alteration: 3 ears with mixed hearing loss (one
with a mild hearing loss and 2 with a moderate hearing
loss).
The other 29 ears presented sensorineural hearing loss of
unknown etiology: 4 ears showed mild sensorineural
hearing loss, 10 ears exhibited sensorial hearing loss at fre-
quencies above 1 KHz, 10 ears had hearing loss above 2
KHz and 5 ears showed hearing loss at frequencies above
3 KHz.
The pre treatment hearing loss etiology may have had a
clinical diagnosis of presbycusis because of the age of the
patients. Patients that had known causes of hearing loss
were excluded as described in Methods.
In the analysis of the data obtained, it was possible to ver-
ify that the average of the frequencies analyzed from 0.25
kHz to 8 kHz were shown to be significantly overset when
comparing pre- and post-treatment, as shown on figure 1
and Table 2, which also shows data referring to the stand-
ard deviation, confidence interval and p-value for each
frequency bilaterally.
According to the ASHA criteria, described above, 70.5%
(12 left ears) and 64.7% (11 right ears) presented
decreased hearing soon after the treatment.
The frequencies of 1 kHz and 8 kHz presented smaller and
larger auditory alteration (respectively), bilaterally.
The cumulative dose of chemotherapy > 300 mg/m2, the
dose by cycle > 50 mg/m2 and the total dose of radiother-
apy > 70.2 Gy did not show association with decreased
hearing, according to Fisher exact test statistical analysis.
The only factors associated to this decreased hearing,
according to the ASHA criteria were the age ≤ 60 years (p
= 0.046) and VTRT > 1500 cm3 (p = 0.016) (Table 3).
Table 1: Demonstrates data referring to gender, age, tumor localization, distribution by clinical staging, number of chemotherapy 
cycles, cumulative dose of cisplatin, dose by fraction and total dose of radiotherapy and the volume of radiotherapy treatment (n = 
17).
Gender Age Localization Staging Clínico Number of 
cycles QT
Total Dose
QT (mg)
Fraction Dose
 RT (Gy)
Total Dose
 RT (Gy)
VRTT
(cm3)
M 54 CEC Larynx T4 N2 M0 7 336 1.8 70.2 1,390
M 49 CEC Larynx T3 N3 M0 5 300 1.8 70.2 2,028
M 71 CEC Hypopharynx T4 N2 M0 5 270 1.8 70.2 2,364
M 51 CEC Hypopharynx T2 N2 M0 7 315 1.8 70.2 1,664
M 61 CEC Oropharynx T4 N2 M0 8 400 1.8 70.2 1,480
M 55 CEC Oral Cavity T2 N2 M0 8 336 1.8 72.2 1,550
M 69 CEC Hard Palate T3 N1 M0 6 270 1.8 70.2 1,306
M 51 CEC Unseen Tx N2 M0 8 220 1.8 70.2 739.64
M 75 CEC Base Tongue T3 N3 M0 7 350 1.8 70.2 2,460
M 69 CEC Oropharynx T4 N0 M0 2 96 2 68 1,392
F 40 CEC Larynx T4 N0 M0 7 455 2 72 1,614
M 57 CEC Larynx T4 N0 M0 6 258 1.8 70.2 1,488
M 64 CEC Larynx T3 N3 M0 7 364 2 64 2,258
M 58 CEC Hypopharynx T4 N3 M0 3 144 1.8 70.2 1,754
F 68 CEC Unseen Tx N2 M0 7 378 2 60 3,364
M 70 CEC Oral Cavity T2 N1 M0 7 399 2 64 1,728
M 54 CEC Oropharynx T3 N0 M0 4 192 1.8 70.2 2,925Radiation Oncology 2009, 4:53 http://www.ro-journal.com/content/4/1/53
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Results about EOAE-DP and acoustic reflexes were ana-
lyzed but they did not show statistical significance. EOAE-
DP were absent in most patients before treatment. In oth-
ers, was not possible to realize this exam due to large noisy
respiration.
Discussion
The Radiotherapy is one of the most effective treatments
for head and neck tumors.
For initial lesions T1 and T2, the results of exclusive use of
RT are comparable to the ones obtained using surgical
procedures. For lesions in a more advanced degree, as
some head and neck anatomical sites, RT associated to CT
has been preferred, due to the possibility of preserving the
organ. The complications of the radiotherapy are specific
sites, in other words, they depend on the area (radiother-
apy field) in which the radiation is being applied.
Specifically for the advanced disease, due to the presence
of voluminous tumors, there is a need to irradiate the pri-
mary site and suspicious areas of microscopic disease. A
potential gamma of complications mainly to healthy tis-
sues close to the tumoral layer may appear as a conse-
quence. As an example, we can mention ototoxicity in
cases of RT on the head and neck area.
Our study observed an important correlation between
VRT and auditory acuity. (Table 3)
In spite of not having performed RT by 3-D image, we
have estimated the VRT for each patient using the techni-
cal parameters of simulation and treatment. It was not
possible to estimate the exact amount of radiation dose
received by the cochlea. However it was observed that the
patients that received VRT >1,500 cm3 were the ones that
presented more auditory damage.
The probable explanation for this discovery is that the
patients that received VRT > 1,500 had the cochlea irradi-
ated with doses above 45 Gy. This fact, possibly, has led
these patients to receive radiation doses in the cochlea
between 50 and 60 Gy, while patients that received VRT <
1,500, after this dose (45 Gy), had the cochlea or part of
it out of the RT field.
Few studies have evaluated the effect of the volume of irra-
diated treatment and the relationship of the total dose of
RT received by the cochlea with its irradiated volume, as a
prognostic factor for the reduction of auditory acuity.
What is known is the relationship between the punctual
dose of radiation received by the cochlea when the three-
dimensional conformed equipment of RT is used, as
shown by Chen et al., who evaluated 22 patients submit-
ted to chemo-radiation [3]. They observed that in the fre-
quencies of 3,000 and 2,000 Hz, the mean dose of
radiotherapy > 48 Gy and time (12 months) were signifi-
cant in multivariate and univariate analyses, whereas the
total dose of cisplatin was not shown to have a statistically
Demonstrates the average differences between pre and pos-treatment air conduction hearing thresholds in decibel, for the fre- quencies ranging from 250 HZ to 8 KHz, in left and right ears, for the 17 patients analyzed Figure 1
Demonstrates the average differences between pre and pos-treatment air conduction hearing thresholds in 
decibel, for the frequencies ranging from 250 HZ to 8 KHz, in left and right ears, for the 17 patients analyzed.Radiation Oncology 2009, 4:53 http://www.ro-journal.com/content/4/1/53
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significant contribution to the change in hearing thresh-
olds.3 In that study, a statistically significant contribution
from cochlear mean dose (Dmean) was seen, but not cis-
platin, suggesting that after more than12 months post-
treatment the radiation dose may supersede cisplatin in
affecting long-term sensorineural sequelae. The ototoxic
effect of radiotherapy found in our study, shows the rela-
tionship between the radiotherapy treatment volume and
Dmean in cochlea. Patients irradiated with VRT > 1,500
cm3 probably received total doses of radiotherapy higher
than 48 Gy in cochlea. Data suggest that the total dose of
radiation may supersede cisplatin in a short follow-up.
Regarding the treatment dose of radiotherapy, results of
our statistical analysis do not show significance for the
decreased hearing post-treatment in patients that received
doses higher than 70.2 Gy of radiation. It is important to
highlight that this radiation dose is the total area dose of
the performed treatment and not the dose received by the
cochlea.
A recent study reported that sensorineural hearing loss is
a potential complication after RT due to cochlear damage.
Herrman et al observed significant reduced hearing abil-
ity, starting with high frequencies at 40 Gy, subsequently
progressing to deeper frequencies at 60 Gy and post-RT
[4].
Other studies that compared patients treated only with
radiotherapy and patients treated with chemo and con-
comitant radiotherapy describe higher risk of hearing loss
in the second group [5,6]. Therefore, we cannot rule out
the possibility of a cumulative effect and potentiation of
the combined treatment.
The ototoxicity caused by cisplatin happens acutely, being
its collateral effects seen in the first days after its use. The
audiological changes are typically bilateral, irreversible
and progressive; they begin in high frequencies with sub-
sequent extension for medium and low frequencies as the
number of cycles increases [6].
Some reports show that when the cumulative dose of cis-
platin reaches 240 mg/m2, a significant loss of the high
frequencies starts to happen, and the ototoxity increases
as the accumulated dose increases. Others show 400 mg/
m2 as a damaging dose [7,8].
Ho et al. reported that the mean dose of 275 mg/m2 of cis-
platin was not associated to the increase of hearing thresh-
old [9]. That result is in accordance with our data. The
dose of cisplatin used in our group of patients was rela-
tively low (96-455 mg/m2, mean dosage 299 mg). Our
statistical analysis, did not show significant correlations
between the total CT dose and the increase of the hearing
thresholds, being the average and the median dose 300
mg/m2 (p = 0.393). (Tables 3)
Table 2: Demonstrates the difference between the averages of air conduction tonal thresholds pre and post-treatment by frequency by 
ear, standard deviation, confidence interval and p-value.
Frequence Diference between the pré- 
and post-treatment average
Standard Deviation 95% Diference
Confidence Interval
p-Valor
Inferior Limit Superior Limit
LEFT EAR 250 -2.94 4.69 -5.35 -0.52 0.02
500 -2.94 3.97 -4.98 -0.89 0.008
1 KHz -1.17 3.32 -2.88 0.53 0.163
2 KHZ -4.41 7.68 -8.36 -0.46 0.031
3 KHz -6.47 11.42 -12.34 -0.59 0.033
4 KHz -9.11 9.22 -13.86 -4.37 0.001
6 KHZ -5.00 8.47 -9.35 -0.64 0.027
8 KHz -11.47 9.31 -16.25 -6.68 0.00
RIGHT EAR 250 -5.00 5.30 -7.72 -2.27 0.001
500 -1.76 3.03 -3.32 -0.20 0.029
1 KHz -0.88 2.64 -2.24 -0.47 0.188
2 KHZ -1.76 4.30 -3.98 -0.45 0.111
3 KHz -7.64 8.12 -11.82 -3.47 0.001
4 KHz -5.29 4.83 -7.77 -2.8 0.00
6 KHZ -12.05 11.59 -18.02 -6.09 0.001
8 KHz -15.00 14.03 -22.21 -7.78 0.00Radiation Oncology 2009, 4:53 http://www.ro-journal.com/content/4/1/53
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The age of patients submitted to the treatment has also
been evidenced as a factor in the increase of the auditory
acuity reduction risk [10,11].
In our study, all the patients analyzed presented age ≥ 40
years old, (average age of 60 years old). In the statistical
analysis, it was verified that the patients < 60 years old pre-
sented 4.54 times higher chance to increase hearing ability
after the treatment.
Regarding the alteration in the hearing thresholds soon
after the end of the chemo- and radiotherapy treatment,
we have found in our sample a larger increase of the hear-
ing thresholds for frequencies from 3 KHz to 8 KHz, for
both left and right ears.
All patients included presented auditory damage: 70.5%
of them with significant auditory alteration; 55.8% with
change equal or higher than 20 dB in a unique frequency
(first ASHA criterion for ototoxity); and 14.7% with
reduction of 10 dB in at least two consecutive frequencies
(second ASHA criterion for ototoxity).
These data are in accordance with the results of Pearson et
al., who retrospectively evaluated audiological findings in
15 patients with head and neck tumors, treated with
radio- and concomitant chemotherapy, using the same
criteria to define ototoxicity. Their results showed that
85% of patients presented changes in frequencies from 4
to 8 kHz and more than 50% of them presented a change
equal to or higher than 10 dB [1].
Other studies illustrate that auditory deficiency happens
in 9% to 91% of the patients, usually bilateral and ini-
tially in the high frequencies (4.000-8.000 Hz), also
affecting the medium and low frequencies with extended
Table 3: Demonstrates the relation between the probability of occurrence to the probability of non-occurrence of an auditory damage 
after chemoradiotherapy treatment, being taken into consideration the variables age, volume and dose of RT and total and cycle dose 
of CT.
Age Total p-Valor
≤ 60 years > 60 years
Auditory damage Yes 9 4 13 0.046
ASHA No 7 14 21
Total 16 18 34
RT Volume Total p-Value
≤ 1500 cm > 1500 cm
Auditory alteration Yes 8 5 13 0.016
ASHA No 4 17 21
Total 12 22 34
RT Total Dose Total p-Value
≤ 70.2 Gy > 70.2 Gy
Auditory damage Yes 3 10 13 0.182
ASHA No 5 16 21
Total 8 26 34
CT Dose Total Total p-Value
≤ 300 mg > 300 mg
Auditory damage Yes 7 6 13 0.393
ASHA No 9 12 21
Total 16 18 34
CT Dose per Cycle Total p-Value
≤ 50 mg > 50 mg
Auditory damage Yes 9 4 13 0.272
ASHA No 11 10 21
Total 20 14 34Radiation Oncology 2009, 4:53 http://www.ro-journal.com/content/4/1/53
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treatment. The auditory deficiency may present a certain
degree of reversibility, when the auditory deficiency is not
deep [12,13].
In a prospective study, Ho et al. evaluated 526 ears of
patients with nasopharyngeal cancer treated exclusively
with radiotherapy [9]. Within a 4.5-year period of follow
up, they observed that the auditory alterations began soon
after the end of the radiotherapy. After two years, 40% of
the patients partially recovered the auditory alteration,
while the other 60% presented worsening auditory defi-
ciency year after year.
Regarding the auditory complaints presented by the
patients, many studies have reported appearance of tinni-
tus. Some of them report that the tinnitus is usually tran-
sitory, disappearing some hours or weeks after the end of
the treatment in 2% to 36% of the patients [12,13]. In a
recent study performed by Zocoli et al., 46% of the
patients presented tinnitus after the second cisplatin
application, which remained until the end of the treat-
ment [14].
In our study, two patients complained about tinnitus dur-
ing the treatment but it disappeared after the end of it.
Two complained about otalgia throughout treatment, and
one presented descamative otitis externa, also throughout
treatment.
Conclusion
Patients with head and neck cancer submitted to conven-
tional radiotherapy treatment combined with the chemo-
therapy, presented a high incidence of decreased hearing
by the end of the treatment.
The main factor associated with this auditory damage was
the volume of radiotherapy treatment.
Our data highlighted the importance of making the audi-
tory evaluation, pre and post-treatment, in all patients
submitted to conventional radiotherapy treatment com-
bined with chemotherapy with cisplatin for head and
neck tumors.
Thus, we stress the importance of the side effects conse-
quences of the treatment, so that the patients can be early
inserted in programs of auditory rehabilitation.
Final considerations
All the patients that presented auditory degradation in fre-
quencies responsible for speech audibility were led to the
use of hearing aids. The three patients who reported daily
auditory difficulties and interest in using hearing aids
were directed and enrolled in the Hearing Aid Program of
this Institution.
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